Viking Therapeutics (VKTX) vs Xenon Pharmaceuticals (XENE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Xenon Pharmaceuticals (XENE) has outperformed Viking Therapeutics (VKTX) over the past year, losing 7.0% versus a loss of 9.5%. Over five years, VKTX leads with a +374.9% price change compared with +8.2% for XENE. Viking Therapeutics is the larger company by market cap ($3.63 billion vs $3.53 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VKTX | XENE |
|---|---|---|
| Share price | $28.54 | $36.41 |
| Market cap | $3.63B | $3.53B |
| 1-day change | +0.56% | -0.44% |
| YTD return | -18.87% | -18.76% |
| 1-year return | -9.50% | -7.02% |
| 5-year return | +374.88% | +8.17% |
| EPS (TTM) | $-4.67 | $-4.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $7.50M |
| Net income (latest FY) | $-359.64M | $-345.91M |
| Operating margin | — | -4974.27% |
| Net margin | — | -4612.13% |
| 52-week high | $43.15 | $72.66 |
| 52-week low | $25.77 | $35.75 |
| Distance from 52-week high | -33.86% | -49.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +231.85% | +101.51% |
| Average volume | 4.00M | 1.47M |
| Shares outstanding | 127.17M | 96.84M |
| Employees | 65 | 358 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Xenon Pharmaceuticals
XENE stock →Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees
VKTX vs XENE FAQ
Which is bigger, Viking Therapeutics or Xenon Pharmaceuticals?
Viking Therapeutics (VKTX) is larger, with a market capitalization of $3.63B compared with $3.53B for Xenon Pharmaceuticals (XENE).
Which stock has performed better over the past year, VKTX or XENE?
XENE returned -7.02% over the past 12 months, compared with -9.50% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Are Viking Therapeutics and Xenon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.